RH
Ronald Kirk Huntsman
Chief Executive OfficerDirector

Ronald Kirk Huntsman insider trades: Vivos Therapeutics (VVOS) stock purchases

Chief Executive Officer, Vivos Therapeutics Last trade Jun 20, 2023 14 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
10
Open-market trades
since 2020
1
Company
last trade 2023

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Ronald reports to the SEC

Open-market buys and sales

10 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jun 20, 2023VVOS↑ Buy$7K
Jun 16, 2023VVOS↑ Buy$8K
Jun 14, 2023VVOS↑ Buy$5K
Dec 23, 2022VVOS↑ Buy$10K
Jun 1, 2022VVOS↑ Buy$24K
Sep 21, 2021VVOS↑ Buy$22K
Aug 17, 2021VVOS↑ Buy$15K
May 25, 2021VVOS↑ Buy$22K
Dec 23, 2020VVOS↑ Buy$7K
Dec 11, 2020VVOS↑ Buy$4K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other VVOS insiders

Open-market trades in the last 12 months

About Ronald Kirk Huntsman's insider trades

Ronald Kirk Huntsman is Chief Executive Officer at Vivos Therapeutics (VVOS). Since Dec 11, 2020, Ronald has reported 10 open-market purchases worth $124K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (4 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every VVOS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.